AnaptysBio (ANAB) Stock Forecast & Price Target
ANAB Analyst Ratings
Strong Buy
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to AnaptysBio in the past 3 months
ANAB Stock 12 Month Forecast
Average Price Target
MXN 1,447.54▲(116.70% Upside)Based on 6 Wall Street analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is MXN 1,447.54 with a high forecast of MXN 1,776.70 and a low forecast of MXN 1,122.12. The average price target represents a 116.70% change from the last price of MXN 668.00.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 1.78K
AverageMXN 1.45K
LowMXN 1.12K
Highest Price TargetHighestMXN 1,776.70Average Price TargetMXN 1,447.54Lowest Price TargetLowestMXN 1,122.12
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Joseph Pantginis | H.C. Wainwright | MXN 972.51→MXN 1,776.70 | buy | 165.97%Upside | Reiterated | 10/26/26 | ||
| David Risinger | Leerink Partners | MXN 1,514.87 | buy | 126.78%Upside | Reiterated | 10/21/26 | ||
| Anupam Rama | J.P. Morgan | MXN 1,309.15→MXN 1,122.12 | buy | 67.98%Upside | Assigned | 09/30/26 | ||
| Michael Yee | UBS | MXN 1,421.36 | buy | 112.78%Upside | Assigned | 09/22/26 | ||
| Etzer Darout | Barclays | MXN 1,402.66 | buy | 109.98%Upside | Reiterated | 09/22/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Assigned | 08/25/26 | ||
| Yasmeen Rahimi | Piper Sandler | MXN 1,739.29 | buy | 160.37%Upside | Reiterated | 07/21/26 | ||
| David Nierengarten | Wedbush | MXN 1,122.12→MXN 1,402.66 | buy | 109.98%Upside | Reiterated | 03/31/26 | ||
| Yatin Suneja | Guggenheim | MXN 2,618.29 | buy | 291.96%Upside | Reiterated | 03/04/26 | ||
| Derek Archila | Wells Fargo | MXN 1,514.87 | buy | 126.78%Upside | Reiterated | 12/16/25 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Joseph Pantginis | 10/26/26 | MXN 972.51→MXN 1,776.70 | buy | 165.97%Upside | Reiterated | H.C. Wainwright | ||
| David Risinger | 10/21/26 | MXN 1,514.87 | buy | 126.78%Upside | Reiterated | Leerink Partners | ||
| Anupam Rama | 09/30/26 | MXN 1,309.15→MXN 1,122.12 | buy | 67.98%Upside | Assigned | J.P. Morgan | ||
| Michael Yee | 09/22/26 | MXN 1,421.36 | buy | 112.78%Upside | Assigned | UBS | ||
| Etzer Darout | 09/22/26 | MXN 1,402.66 | buy | 109.98%Upside | Reiterated | Barclays | ||
| Joseph Thome | 08/25/26 | ― | buy | ― | Assigned | TD Cowen | ||
| Yasmeen Rahimi | 07/21/26 | MXN 1,739.29 | buy | 160.37%Upside | Reiterated | Piper Sandler | ||
| David Nierengarten | 03/31/26 | MXN 1,122.12→MXN 1,402.66 | buy | 109.98%Upside | Reiterated | Wedbush | ||
| Yatin Suneja | 03/04/26 | MXN 2,618.29 | buy | 291.96%Upside | Reiterated | Guggenheim | ||
| Derek Archila | 12/16/25 | MXN 1,514.87 | buy | 126.78%Upside | Reiterated | Wells Fargo |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering AnaptysBio
3 Months
Success Rate11/17 ratings generated profit
65%
Average Return
+21.30%
Copying Anupam Rama's trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +21.30% per trade.
1 Year
Success Rate12/17 ratings generated profit
71%
Average Return
+99.84%
Copying Anupam Rama's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +99.84% per trade.
2 Years
Success Rate13/13 ratings generated profit
100%
Average Return
+228.72%
Copying Derek Archila's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +228.72% per trade.
ANAB Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 3 | 5 | 6 | 8 |
| Buy | 14 | 14 | 7 | 11 | 6 |
| Hold | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 15 | 17 | 12 | 18 | 15 |
In the current month, ANAB has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ANAB average Analyst price target in the past 3 months is 1,447.54.
ANAB Financial Forecast
ANAB Stock Forecast FAQ
What is MX:ANAB’s average 12-month price target, according to analysts?
Based on analyst ratings, AnaptysBio’s 12-month average price target is Mex$1,447.54.
What is MX:ANAB’s upside potential, based on the analysts’ average price target?
AnaptysBio has 116.70% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AnaptysBio a Buy, Sell or Hold?
AnaptysBio has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is AnaptysBio’s share price target?
The average share price target for AnaptysBio is Mex$1,447.54. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$1,776.70, and the lowest forecast is Mex$1,122.12. The average share price target represents a 116.70% increase from the current price of Mex$668.
What do analysts say about AnaptysBio?
AnaptysBio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of AnaptysBio?
To buy shares of MX:ANAB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
